AR114090A1 - Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos para hacer y usar el mismo - Google Patents

Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos para hacer y usar el mismo

Info

Publication number
AR114090A1
AR114090A1 ARP190100236A ARP190100236A AR114090A1 AR 114090 A1 AR114090 A1 AR 114090A1 AR P190100236 A ARP190100236 A AR P190100236A AR P190100236 A ARP190100236 A AR P190100236A AR 114090 A1 AR114090 A1 AR 114090A1
Authority
AR
Argentina
Prior art keywords
same
compound
salts
formulations
methods
Prior art date
Application number
ARP190100236A
Other languages
English (en)
Inventor
Ludwig Pilsl
Rajendra Tandale
Ramachandran Radhakrishnan
Manshiu Leung
Srikonda Sastry
Fritz Blatter
Wei Zhang
Shuai Wang
Yuan Liu
Karthik Nagapudi
Roland Mller
Markus Frieser
Christine Czauderna
Lawrence Emerson Fisher
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR114090A1 publication Critical patent/AR114090A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un compuesto, caracterizado porque es una sal de 1-metil-7-(1-metil-1H-pirazol-4-il)-5-4-(trifluorometoxi)fenil)-1,5-dihidro-4H-imidazo[4,5-c]piridin-4-ona (Compuesto I) de fórmula (1), con la condición que la sal no sea una sal de clorhidrato del Compuesto I. Reivindicación 2: El compuesto de conformidad con la reivindicación 1, caracterizado porque se selecciona del grupo que consiste en sales debesilato, citrato, fumarato, hemi-edisilato, hemi-napadisilato, bromhidrato, maleato, nicotinato, nitrato, oxalato, fosfato, sacarinato, sulfato, L-tartrato y tosilato del Compuesto I.
ARP190100236A 2018-02-02 2019-02-01 Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos para hacer y usar el mismo AR114090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018075023 2018-02-02

Publications (1)

Publication Number Publication Date
AR114090A1 true AR114090A1 (es) 2020-07-22

Family

ID=65494537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100236A AR114090A1 (es) 2018-02-02 2019-02-01 Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos para hacer y usar el mismo

Country Status (18)

Country Link
US (1) US20200361933A1 (es)
EP (1) EP3746441B1 (es)
JP (2) JP7372926B2 (es)
KR (1) KR20200118098A (es)
CN (2) CN112105616B (es)
AR (1) AR114090A1 (es)
AU (2) AU2019215172B2 (es)
BR (1) BR112020015759A2 (es)
CA (1) CA3090270A1 (es)
ES (1) ES2949662T3 (es)
HR (1) HRP20230645T1 (es)
IL (2) IL312673A (es)
MX (2) MX2020008076A (es)
PL (1) PL3746441T3 (es)
SG (1) SG11202007726RA (es)
SI (1) SI3746441T1 (es)
TW (2) TW202426448A (es)
WO (1) WO2019152863A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160410A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用
CN116509850A (zh) * 2022-01-21 2023-08-01 苏州爱科百发生物医药技术有限公司 N-芳基吡啶酮类化合物在尘肺治疗中的用途
WO2023219106A1 (ja) * 2022-05-10 2023-11-16 Ｍｙｒｏｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 ２－メチル－２－チアゾリンの塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1176956T3 (da) * 1999-05-07 2008-05-26 Encysive Pharmaceuticals Inc Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
BRPI0720862A2 (pt) * 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102373700B1 (ko) * 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
PL3383397T3 (pl) * 2015-12-02 2021-12-27 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne zawierające dorawirynę, fumaran dizoproksylu tenofowiru i lamiwudynę

Also Published As

Publication number Publication date
IL312673A (en) 2024-07-01
US20200361933A1 (en) 2020-11-19
SG11202007726RA (en) 2020-09-29
AU2023222929A1 (en) 2023-09-21
IL276430B1 (en) 2024-06-01
ES2949662T3 (es) 2023-10-02
MX2020011756A (es) 2021-06-23
EP3746441B1 (en) 2023-04-05
SI3746441T1 (sl) 2023-08-31
CN112105616A (zh) 2020-12-18
EP3746441A1 (en) 2020-12-09
JP2021512118A (ja) 2021-05-13
TW201940482A (zh) 2019-10-16
TWI834634B (zh) 2024-03-11
MX2020008076A (es) 2020-09-24
IL276430A (en) 2020-09-30
AU2019215172B2 (en) 2023-08-10
CN112105616B (zh) 2023-09-01
AU2019215172A1 (en) 2020-08-20
CN117247383A (zh) 2023-12-19
BR112020015759A2 (pt) 2020-12-08
WO2019152863A1 (en) 2019-08-08
CA3090270A1 (en) 2019-08-08
JP7372926B2 (ja) 2023-11-01
IL276430B2 (en) 2024-10-01
KR20200118098A (ko) 2020-10-14
TW202426448A (zh) 2024-07-01
PL3746441T3 (pl) 2023-07-31
HRP20230645T1 (hr) 2023-09-29
JP2023145680A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
AR114090A1 (es) Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos para hacer y usar el mismo
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
BR112019006816A8 (pt) Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos
PE20190910A1 (es) Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih
CL2018002358A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
UY37998A (es) Agentes antivirales contra la hepatitis b
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR108265A1 (es) Derivados de feniltriazol sustituidos con amida y usos de estos
AR119614A1 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
AR103110A1 (es) Métodos de combinación para el tratamiento de cánceres
EA201990235A1 (ru) ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC
AR080802A1 (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro
CO2022001853A2 (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
AR102463A1 (es) Inhibidor de cinasa aurora a
CL2018001808A1 (es) Productos combinados para el tratamiento de rsv.
AR092489A1 (es) Inhibidores de proteasa del vih
PH12019500822A1 (en) Crystalline forms of eravacycline
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
AR092713A1 (es) Composiciones y metodos de uso de un compuesto para el control de la inapetencia
AR101806A1 (es) Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio
AR128248A2 (es) Mezclas herbicidas con auxina